F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review

Bibliography

• Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: Genetic analysis. Science 1989;245:1073-80
   PubMed Web of Science ®Google Scholar
• Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 1989;245:1066-73
   PubMed Web of Science ®Google Scholar
• Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: Chromosome walking and jumping. Science 1989;245:1059-65
   PubMed Web of Science ®Google Scholar
• American Lung Association. In: State of Lung Disease in Diverse Communities 2010. 2010;41-4. Available from: http://www.lung.org/assets/documents/publications/lung-disease-data/solddc_2010.pdf [Last accessed 1 January 2015]
   Google Scholar
• Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros 2008;7:450-3
   PubMed Web of Science ®Google Scholar
• Trezise AE, Buchwald M. In vivo cell-specific expression of the cystic fibrosis transmembrane conductance regulator. Nature 1991;353:434-7
   PubMed Web of Science ®Google Scholar
• Kunzelmann K. The cystic fibrosis transmembrane conductance regulator and its function in epithelial transport. Rev Physiol Biochem Pharmacol 1999;137:1-70
   PubMedGoogle Scholar
• Riordan JR. CFTR function and prospects for therapy. Ann Rev Biochem 2008;77:701-26
   PubMed Web of Science ®Google Scholar
• Crawford I, Maloney PC, Zeitlin PL, et al. Immunocytochemical localization of the cystic fibrosis gene product CFTR. Proc Natl Acad Sci U S A 1991;88:9262-6
   PubMed Web of Science ®Google Scholar
• Frizzell RA, Hanrahan JW. Physiology of epithelial chloride and fluid secretion. Cold Spring Harb Perspect Med 2012;2:a009563
   Google Scholar
• Chambers LA, Rollins BM, Tarran R. Liquid movement across the surface epithelium of large airways. Respir Physiol Neurobiol 2007;159:256-70
   PubMed Web of Science ®Google Scholar
• Thiagarajah JR, Verkman AS. CFTR pharmacology and its role in intestinal fluid secretion. Curr Opin Pharmacol 2003;3:594-9
   PubMed Web of Science ®Google Scholar
• Venkatasubramanian J, Ao M, Rao MC. Ion transport in the small intestine. Curr Opin Gastroenterol 2010;26:123-8
   PubMed Web of Science ®Google Scholar
• Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993;73:1251-4
   PubMed Web of Science ®Google Scholar
• O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373:1891-904
   PubMed Web of Science ®Google Scholar
• Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest 2011;139:1480-90
   PubMed Web of Science ®Google Scholar
• Gazvani R, Lewis-Jones I. Cystic fibrosis screening in assisted reproduction. Curr Opin Obstet Gynecol 2006;18(3):268-72
   PubMed Web of Science ®Google Scholar
• Denning GM, Ostedgaard LS, Welsh MJ. Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epithelia. J Cell Biol 1992;118:551-9
   PubMed Web of Science ®Google Scholar
• Dalemans W, Barbry P, Champigny G, et al. Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 1991;354:526-8
   PubMed Web of Science ®Google Scholar
• Kartner N, Augustinas O, Jensen TJ, et al. Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland. Nat Genet 1992;1:321-7
   PubMed Web of Science ®Google Scholar
• Dalemans W, Hinnrasky J, Slos P, et al. Immunocytochemical analysis reveals differences between the subcellular localization of normal and delta Phe508 recombinant cystic fibrosis transmembrane conductance regulator. Exp Cell Res 1992;201:235-40
   PubMed Web of Science ®Google Scholar
• Ng MY, Flight W, Smith E. Pulmonary complications of cystic fibrosis. Clin Radiol 2014;69:e153-62
   PubMedGoogle Scholar
• Dhooghe B, Noël S, Huaux F, Leal T. Lung inflammation in cystic fibrosis: pathogenesis and novel therapies. Clin Biochem 2014;47:539-46
   PubMed Web of Science ®Google Scholar
• McCaughey G, Gilpin D, Elborn J, Tunney MM. The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection. Expert Rev Respir Med 2013;7:385-96
   PubMed Web of Science ®Google Scholar
• Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care 2009;54:595-605
   PubMed Web of Science ®Google Scholar
• Jain M, Goss CH. Update in cystic fibrosis 2013. Am J Respir Crit Care Med 2014;189:1181-6
   PubMed Web of Science ®Google Scholar
• Grasemann H, Ratjen F. Early lung disease in cystic fibrosis. Lancet Respir Med 2013;1:148-57
   PubMed Web of Science ®Google Scholar
• Chmiel JF, Konstan MW, Elborn JS. Antibiotic and anti-inflammatory therapies for cystic fibrosis. Cold Spring Harb Perspect Med 2013;3:a009779
   PubMed Web of Science ®Google Scholar
• Wilson R, Sethi S, Anzueto A, Miravitlles M. Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease. J Infect 2013;67:497-515
   PubMed Web of Science ®Google Scholar
• Peters S. Cystic fibrosis: a review of pathophysiology and current treatment recommendations. S D Med 2014;67:148-51, 153
   PubMedGoogle Scholar
• Ratjen F, Döring G. Cystic fibrosis. Lancet 2003;361:681-9
   PubMed Web of Science ®Google Scholar
• Ratjen F. New pulmonary therapies for cystic fibrosis. Curr Opin Pulm Med 2007;13:541-6
   PubMed Web of Science ®Google Scholar
• Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Opin Pulm Med 2006;12:428-32
   PubMed Web of Science ®Google Scholar
• Atkinson TJ. Cystic fibrosis, vector-mediated gene therapy, and relevance of toll-like receptors: a review of problems, progress, and possibilities. Curr Gene Ther 2008;8:201-7
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Cunningham S, Davies JC, Alton EW. Gene therapy in cystic fibrosis. Arch Dis Child 2014;99:465-8
   PubMed Web of Science ®Google Scholar
• Griesenbach U, Alton EW. Moving forward: cystic fibrosis gene therapy. Hum Mol Genet 2013;22:R52-8
   PubMed Web of Science ®Google Scholar
• Prickett M, Jain M. Gene therapy in cystic fibrosis. Transl Res 2013;161:255-64
   PubMed Web of Science ®Google Scholar
• Denning G, Anderson M, Amara J, et al. Processing of mutant cytsic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992;358:761-3
   PubMed Web of Science ®Google Scholar
• Sato S, Ward CL, Krouse ME, et al. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 1996;271:635-8
   PubMed Web of Science ®Google Scholar
• Brown CR, Hong-Brown LQ, Biwersi J, et al. Chemical chaperones correct the mutant phenotype of the ΔF508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1996;1:117-25
   PubMed Web of Science ®Google Scholar
• Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in F508del-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998;157:484-90
   PubMed Web of Science ®Google Scholar
• Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 1997;100:2457-65
   PubMed Web of Science ®Google Scholar
• Rowe SM, Verkman AS. Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med 2013;3(7):pii: a009761
   Google Scholar
• Pettit RS. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Ann Pharmacother 2012;46:1065-75
   PubMed Web of Science ®Google Scholar
• Deeks ED. Ivacaftor: a review of its use in patients with cystic fibrosis. Drugs 2013;73:1595-604
   PubMed Web of Science ®Google Scholar
• Merk D, Schubert-Zsilavecz M. Repairing mutated proteins--development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator. Expert Opin Drug Discov 2013;8:691-708
   PubMed Web of Science ®Google Scholar
• Pasyk S, Molinski S, Yu W, et al. Identification and validation of hits from high throughput screens for CFTR modulators. Curr Pharm Des 2012;18:628-41
   PubMed Web of Science ®Google Scholar
• Becq F. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date. Drugs 2010;70:241-59
   PubMed Web of Science ®Google Scholar
• Pettit RS, Fellner C. CFTR. Modulators for the Treatment of Cystic Fibrosis. P T 2014;39:500-11
   PubMedGoogle Scholar
• Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov 2009;8:153-71
   PubMed Web of Science ®Google Scholar
• Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 2011;108:18843-8
   PubMed Web of Science ®Google Scholar
• Pedemonte N, Sonawane ND, Taddei A, et al. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005;67:1797-807
   PubMed Web of Science ®Google Scholar
• Yang H, Shelat AA, Guy RK, et al. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J Biol Chem 2003;278:35079-85
   PubMed Web of Science ®Google Scholar
• Pettit RS, Fellner C. CFTR. Modulators for the Treatment of Cystic Fibrosis. P T 2014;39:500-11
   PubMedGoogle Scholar
• Vertex Pharmaceuticals. U.S. Food and Drug Administration Approves KALYDECO™ (ivacaftor) for Use in Eight Additional Mutations that Cause Cystic Fibrosis. 2014. Available from: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=827435 [Last accessed on 28 January 2015]
   Google Scholar
• Ren HY, Grove DE, De La Rosa O, et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell 2013;24:3016-24
   PubMed Web of Science ®Google Scholar
• Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67:12-18
   PubMed Web of Science ®Google Scholar
• Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2014;2:527-38
   PubMed Web of Science ®Google Scholar
• A study of lumacaftor in combination with ivacaftor in cystic fibrosis subjects aged 12 years and older who are homozygous for the F508del-CFTR mutation (TRANSPORT). Available from: https://clinicaltrials.gov/ct2/show/record/NCT01807949 [Last accessed on 16 March 2015]
   Google Scholar
• A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC). Available from: https://clinicaltrials.gov/ct2/show/NCT01807923 [Last accessed on 16 March 2015]
   Google Scholar
• FirstWord Pharma. Vertex’s Kalydeco, lumacaftor combination meets main goals of cystic fibrosis Phase III trials. 2014. Available from: http://www.firstwordpharma.com/node/1219447#axzz3Q5NRiPtZ [Last accessed on 28 January 2015]
   Google Scholar
• Cholon DM, Quinney NL, Fulcher ML, et al. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci Transl Med 2014;6(246):246ra96
   PubMed Web of Science ®Google Scholar
• Seeking Alpha. Vertex Pharma off on trial data for VX-661. 2015. Available from: http://seekingalpha.com/news/2385656-vertex-pharma-off-on-trial-data-for-vxminus-661?auth_param=11sf95:1ah0949:c0eace6e7379e65e5b9216347ff7e872&uprof=. 61 [Last accessed on 23 March 2015]
   Google Scholar
• Norman P. Novel picolinamide-based cystic fibrosis transmembrane regulator modulators: evaluation of WO2013038373, WO2013038376, WO2013038381, WO2013038386 and. WO2013038390. Expert Opin Ther Pat 2014.24(7):829-37
   Google Scholar
• Cystic Fibrosis Foundation Therapeutic INC. Pyrimidine compounds and methods of making and using same. WO068863; 2010
   Google Scholar
• Cystic Fibrosis Foundation Therapeutic INC. Pyrimine compounds and methods of making and using same. WO151747; 2010
   Google Scholar
• Cystic Fibrosis Foundation Therapeutic INC. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders. WO008931; 2011
   Google Scholar
• Verkman AS, Pedemont N, Galietta LJV. Compounds having activity in correcting mutant-CFTR processing and uses thereof. WO101740; 2006
   Google Scholar
• Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005;115:2564-71
   PubMed Web of Science ®Google Scholar
• Ye L, Hu B, El-Badri F, et al. ΔF508-CFTR correctors: Synthesis and evaluation of thiazole-tethered imidazolones, oxazoles, oxadiazoles, and thiadiazoles. Bioorg Med Chem Lett 2014;24:5840-4
   PubMed Web of Science ®Google Scholar
• Donald MB, Rodriguez KX, Shay H, et al. Click-based synthesis of triazolobithiazole ΔF508-CFTR correctors for cystic fibrosis. Bioorg Med Chem 2012;20:5247-53
   PubMed Web of Science ®Google Scholar
• Ye L, Knapp JM, Sangwung P, et al. Pyrazolylthiazole as DeltaF508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared to bithiazoles. J Med Chem 2013;53:3772-81
   Google Scholar
• Yu GJ, Yoo CL, Yang B, et al. Potent s-cis-locked bithiazole correctors of DeltaF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy. J Med Chem 2008;51:6044-54
   PubMed Web of Science ®Google Scholar
• Loo TW, Bartlett MC, Clarke DM. Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound. Mol Pharm 2005;2:407-13
   PubMedGoogle Scholar
• Loo TW, Bartlett MC, Wang Y, Clarke DM. The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutants. Biochem J 2006;395:537-42
   PubMed Web of Science ®Google Scholar
• Van Goor F, Straley KS, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006;290:L1117-30
   PubMed Web of Science ®Google Scholar
• Suen YF, Robins L, Yang B, et al. Sulfamoyl-4-oxoquinoline-3-carboxamides: novel potentiators of defective DeltaF508-cystic fibrosis transmembrane conductance regulator chloride channel gating. Bioorg Med Chem Lett 2006;16:537-40
   PubMed Web of Science ®Google Scholar
• Phuan PW, Yang B, Knapp JM, et al. Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis. Mol Pharmacol 2011;80:683-93
   PubMed Web of Science ®Google Scholar
• Knapp JM, Wood AB, Phuan PW, et al. Structure-activity relationships of cyanoquinolines with corrector-potentiator activity in ΔF508 cystic fibrosis transmembrane conductance regulator protein. J Med Chem 2012;55:1242-51
   PubMed Web of Science ®Google Scholar
• Verkman AS, Phuan P, Kurth MJ, Knapp J. Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof. WO166654; 2012
   Google Scholar
• DiscoveryBiomed INC. Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders. WO152213; 2014
   Google Scholar
• Cabrini G, Casavola V, Gambari R. Trimethylangelicin as cftr corrector in bronchial epithelial cells. WO171954; 2012
   Google Scholar
• Favia M, Mancini MT, Bezzerri V, et al. Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells. Am J Physiol Lung Cell Mol Physiol 2014;307:L48-61
   PubMed Web of Science ®Google Scholar
• Xu LN, Na WL, Liu X, et al. Identification of natural coumarin compounds that rescue defective DeltaF508-CFTR chloride channel gating. Clin Exp Pharmacol Physiol 2008;35:878-83
   PubMed Web of Science ®Google Scholar
• Yang H, Xu LN, Sui YJ, et al. Stimulation of Airway and Intestinal Mucosal Secretion by Natural Coumarin CFTR Activators. Front Pharmacol 2011;2:52
   Google Scholar
• Wu L, Wang X, Xu W, et al. The structure and pharmacological functions of coumarins and their derivatives. Curr Med Chem 2009;16:4236-60
   PubMed Web of Science ®Google Scholar
• DiscoveryBiomed INC. Small molecule bicyclic and tricyclic cftr correctors. WO081821; 2014
   Google Scholar
• DiscoveryBiomed INC. Small molecule cftr correctors. WO081820; 2014
   Google Scholar
• Prehm P. Compounds having activity in correcting mutant CFTR cellular processing. WO066912; 2010
   Google Scholar
• Vertex Pharmaceuticals. Vertex Outlines 2015 Business Priorities to Support the Development, Approval and Launch of New Medicines for the Treatment of People with Cystic Fibrosis. 2015. Available from: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=890626 [Last accessed on 28 January 2015]
   Google Scholar
• Veit G, Avramescu RG, Perdomo D, et al. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci Transl Med 2014;6(246):246ra97
   PubMed Web of Science ®Google Scholar
• Okiyoneda T, Veit G, Dekkers JF, et al. Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Nat Chem Biol 2013;444-54
   PubMed Web of Science ®Google Scholar
• Rabeh WM, Bossard F, Xu H, et al. Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function. Cell 2012;148:150-63
   PubMed Web of Science ®Google Scholar
• Farinha CM, King-Underwood J, Sousa M, et al. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. Chem Biol 2013;20:943-55
   PubMed Web of Science ®Google Scholar
• Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the ΔF508 conformational defect. Trends Mol Med 2012;18:81-91
   PubMed Web of Science ®Google Scholar
• Jiang M, Yang J, Zhang C, et al. Clinical studies with traditional Chinese medicine in the past decade and future research and development. Planta Med 2010;76:2048-64
   PubMed Web of Science ®Google Scholar
• Hsiao WL, Liu L. The role of traditional Chinese herbal medicines in cancer therapy--from TCM theory to mechanistic insights. Planta Med 2010;76:1118-31
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yu B, Sui Y, et al. Identification of resveratrol oligomers as inhibitors of cystic fibrosis transmembrane conductance regulator by high-throughput screening of natural products from chinese medicinal plants. PLoS One 2014;9:e94302
   PubMed Web of Science ®Google Scholar
• Luan J, Zhang Y, Yang S, et al. Oridonin: A small molecule inhibitor of cystic fibrosis transmembrane conductance regulator (CFTR) isolated from traditional Chinese medicine. Fitoterapia 2014;100C:88-94
   Google Scholar
• Chen L, Yu B, Zhang Y, et al. Bioactivity-guided Fractionation of an Antidiarrheal Chinese Herb Rhodiola kirilowii (Regel) Maxim Reveals (-)–epicatechin-3-gallate and (-)–epigallocatechin-3-gallate as Inhibitors of Cystic Fibrosis Transmembrane Conductance Regulator. PLoS ONE 2015;10(3):e0119122
   PubMed Web of Science ®Google Scholar
• Kopeikin Z, Yuksek Z, Yang HY, Bompadre SG. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels. J Cyst Fibros 2014;13:508-14
   PubMed Web of Science ®Google Scholar
• Rowe SM, Verkman AS. Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med 2013;3:a009761
   PubMed Web of Science ®Google Scholar
• Vertex Pharmaceutical Incorporated. Modulators of ATP-binding cassette transporters. WO075435; 2005
   Google Scholar
• Vertex Pharmaceutical Incorporated. Modulators of cystic fibrosis transmembrane conductance regulator. WO021982; 2007
   Google Scholar
• Vertex Pharmaceutical Incorporated. Azaindole derivatives as CFTR modulators. WO127399; 2008
   Google Scholar
• Vertex Pharmaceutical Incorporated. Heteroaryl derivatives as CFTR modulators. WO108657; 2009
   Google Scholar
• Vertex Pharmaceutical Incorporated Pyridyl derivatives as CFTR modulators. WO123896; 2009
   Google Scholar
• Vertex Pharmaceutical Incorporated. Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid. WO112804; 2013
   Google Scholar
• Vertex Pharmaceutical Incorporated. Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof. WO014841; 2014
   Google Scholar